Atherosclerosis:空腹及餐后甘油三酯和颈动脉内膜厚度的关系

2015-09-26 phylis 译 MedSci原创

背景:颈总动脉内膜厚度(CCA-IMT)是动脉粥样硬化的一种检测指标。甘油三酯在CCA-IMT中的作用尚有争议。研究人员旨在确定是否空腹及餐后甘油三酯与CCA-IMT相关。 方法:招募2009年1月到2014年1月期间参与柏林“Cream和Sugar”研究中的急性缺血性卒中患者,并对其进行颈动脉超声检测的患者。第一次缺血性卒中后,对患者进行3-7天口服糖和甘油三酯耐受实验。根据甘油三酯的代谢情况,

背景:颈总动脉内膜厚度(CCA-IMT)是动脉粥样硬化的一种检测指标。甘油三酯在CCA-IMT中的作用尚有争议。研究人员旨在确定空腹及餐后甘油三酯是否与CCA-IMT相关。

方法:招募2009年1月到2014年1月期间参与柏林“Cream和Sugar”研究的急性缺血性卒中患者,并对其进行颈动脉超声检测。第一次缺血性卒中后,对患者进行3-7天口服糖和甘油三酯耐受实验。根据甘油三酯的代谢情况,将患者分成3组,(1)餐后3h患者甘油三酯水平最高(n=37,快速代谢者)(2)餐后4h甘油三酯水平最高(n=64,中等程度代谢)(3)餐后5h甘油三酯水平最高。(n=44;慢代谢者;13名数据丢失)。

结果:该研究共纳入158名患者(34%女性,平均年龄63岁)。空腹甘油三酯水平(非餐后甘油三酯)与CCA-IMT正相关。最终多变量回归模型显示,高龄、较严重的卒中、空腹甘油三酯水平较高与CCA-IMT平均计值较高相关。高龄、高腰臀比、高甲状腺刺激激素(TSH)与CCA-IMT最大计值较高相关。

结论:非餐后甘油三酯,而是空腹甘油三酯而与CCA-IMT相关。餐后血脂可能与缺血性卒中患者动脉粥样硬化状态无关。

原文出处:

Batluk J, Leonards CO, Grittner U,et al.Triglycerides and carotid intima-media thickness in ischemic stroke patients. Atherosclerosis. 2015 Sep 9


版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1947301, encodeId=c45a194e301fa, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Feb 01 11:35:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708320, encodeId=09841e0832031, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Tue Jun 14 16:35:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843393, encodeId=946d18433936a, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sun Nov 01 18:35:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364059, encodeId=db9613640593b, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Sep 28 01:35:00 CST 2015, time=2015-09-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1947301, encodeId=c45a194e301fa, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Feb 01 11:35:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708320, encodeId=09841e0832031, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Tue Jun 14 16:35:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843393, encodeId=946d18433936a, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sun Nov 01 18:35:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364059, encodeId=db9613640593b, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Sep 28 01:35:00 CST 2015, time=2015-09-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1947301, encodeId=c45a194e301fa, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Feb 01 11:35:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708320, encodeId=09841e0832031, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Tue Jun 14 16:35:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843393, encodeId=946d18433936a, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sun Nov 01 18:35:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364059, encodeId=db9613640593b, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Sep 28 01:35:00 CST 2015, time=2015-09-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1947301, encodeId=c45a194e301fa, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Feb 01 11:35:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708320, encodeId=09841e0832031, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Tue Jun 14 16:35:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843393, encodeId=946d18433936a, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sun Nov 01 18:35:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364059, encodeId=db9613640593b, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Sep 28 01:35:00 CST 2015, time=2015-09-28, status=1, ipAttribution=)]
    2015-09-28 lsndxfj

相关威廉亚洲官网

Geriatr Gerontol Int:卒中前痴呆对其缺血性卒中的影响

目的:这篇研究的主要目的是确定卒中前痴呆(PSD)是否影响老年缺血性卒中患者的短期功能预后。方法:对老年缺血性卒中患者进行回顾性病例对照研究。应用功能独立测量量表(FIM)对患者入院和出院时进行功能预后评估。应用t检验,卡方检验,多次线性回归以及logistics回归分析数据。结果:急性缺血性卒中患者919名,其中11.5%诊断为PSD。与非PSD患者相比,PSD患者,存活时间较短,女性患者比例较

Int J Stroke:急性缺血性卒中药物治疗还是血管内血栓切除?

大血管梗塞的急性缺血性卒中患者行静脉溶栓治疗,血管再通效果较差。最近的研究表明血管内治疗,患者血管再通及预后较单纯药物治疗好。系统性综述和meta-分析调查血管内血栓切除术的相关随机对照试验优势,并且至少有25%的患者应用血栓切除设备进行急性缺血性卒中患者治疗,并且这些患者未进行药物治疗。对血管内血栓切除和药物治疗急性缺血性卒中患者的疗效进行系统性综述和meta-分析。williamhill asia 研究选取了437个研究,

Eur J Neurol:患者自述心血管家族史可信吗?

家族史是遗传危险因素的指标。应用家族史这个指标可以反映家族中真正的疾病。这篇研究为了分析中青年缺血性卒中患者自称的心血管疾病(CVD)的家族史和患者父母报告的一致性。应用标准化问卷调查了15-60岁的缺血性卒中的患者和他们父母。登记存在CVD和CVD家族史的患者。应用KAPPA统计分析患者自述和父母报告一致的敏感性,特异性,预测价值以及似然比。应用回归分析非一致性患者的特征。父亲和母亲的的反应率没

BMJ Open:抗癫痫药与缺血性卒中和心肌梗死发生的关系

目的:肝酶诱导的抗癫痫药物(AEDs)通过诱导细胞色素P450增加血浆中的脂质及其他动脉粥样硬化标志物,因此可能会增加血管事件的发生。研究人员根据AED代谢的酶特性旨在评估其对缺血性卒中和心肌梗死(MI)发生的风险。设计:病例对照分析的群体队列研究。英国临床实践研究数据链中的650个普通医生的医业。受试者:招募1990年1月到2013年4月间252407名应用AED的患者,患者年龄在18岁以上。每

脑微出血抗栓治疗的五个问题

1.脑微出血(CMB)的病理生理机制是什么?脑淀粉样血管和高血压微血管病,二者皆可以损害血脑屏障和神经血管单元,血液漏出和含铁血黄素沉积,导致CMB。2.在需要抗栓治疗的患者中CMB常见吗?在需要抗栓治疗的缺血性卒中/TIA患者中,CMB并不罕见,至少占四分之一。3.抗栓治疗会增加CMB的数量吗?抗栓药物包括阿司匹林、氯吡格雷、华法林是否能够增加CMB的数量一直存在争论。一些大型研究发现抗栓治疗会

Clin Chim Acta:血管反应素-1对急性缺血性卒中患者预后的预测价值

血管反应素-1是血管再生的有效调节剂。脑出血的大鼠模型中脑中血管反应素-1的表达增加。当前的研究主要是确定血浆中血管反应素-1浓度的变化以及评估血浆血管反应素-1浓度对缺血性卒中患者长期的死亡率和功能预后的预测价值。这篇研究包括192名患者,150名健康者作为对照。应用酶联免疫吸附试验测定血浆中血管反应素-1的浓度。不利预后以mRS分数大于3为标准。应用多变量分析血浆血管反应素-1浓度和6个月临床